MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/87.5/0.2/17.01.25 | Market Closed - Bid/Ask 17:33:33 26/06/2024 BST | After market 19:41:23 | |||
| 11.3 EUR | -3.67% |
|
11.25 | -0.44% |
| Current month | +25.59% | ||
| 1 month | +20.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 11.3 | -3.67% |
| 25/06/24 | 11.73 | +8.91% |
| 24/06/24 | 10.77 | -1.37% |
| 21/06/24 | 10.92 | +1.49% |
| 20/06/24 | 10.76 | +0.56% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 05:33 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MB23AC |
| ISIN | DE000MB23AC6 |
| Date issued | 05/01/2023 |
| Strike | 87.5 $ |
| Maturity | 17/01/2025 (205 Days) |
| Parity | 5 : 1 |
| Emission price | 1.55 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.73 € |
|---|---|
| Lowest since issue | 1.13 € |
| Spread | 0.02 € |
| Spread % | 0.18% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,028
DKK
Average target price
938.1
DKK
Spread / Average Target
-8.74%
- Stock Market
- Warrants
- Warrant
